Shinkichi Takamori1, Kazuki Takada2, Gouji Toyokawa1, Koichi Azuma3, Mototsugu Shimokawa4, Tomoko Jogo1,5, Yuichi Yamada5, Fumihiko Hirai1, Tetsuzo Tagawa1, Akihiko Kawahara6, Jun Akiba6, Isamu Okamoto7, Yoichi Nakanishi7, Yoshinao Oda5, Tomoaki Hoshino3, Yoshihiko Maehara1. 1. Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. 2. Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan k_takada@surg2.med.kyushu-u.ac.jp. 3. Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan. 4. Clinical Research Institute, National Kyushu Cancer Center, Fukuoka, Japan. 5. Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. 6. Department of Diagnostic Pathology, Kurume University School of Medicine, Fukuoka, Japan. 7. Research Institute for Disease of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Abstract
BACKGROUND/AIM: To investigate the role of programmed cell death-ligand 2 (PD-L2) expression as a predictive biomarker for response to anti-programmed cell death-1 (PD-1) drugs in patients with non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Ten patients who had undergone curative lung resection and received the anti-PD-1 drugs for the recurrence were enrolled. The cut-off value for PD-L2 (antibody clone 176611) expression on tumor cells was set at 50%. Tumor response was evaluated according to immune-related response criteria. RESULTS: Seven patients (70.0%) were positive for PD-L2. The response rates were 28.6% (2/7) and 33.3% (1/3) in patients with PD-L2-positive and PD-L2-negative NSCLC, respectively. Disease control was obtained in 2 patients despite the programmed cell death-ligand 1 (PD-L1)-negativity (antibody clone 22C3: 0%, antibody clone SP142: 0%), and these tumors expressed PD-L2 (≥1%). CONCLUSION: PD-L2 expression may be a target of immunotherapy in patients with PD-L1-negative NSCLC. Copyright
BACKGROUND/AIM: To investigate the role of programmed cell death-ligand 2 (PD-L2) expression as a predictive biomarker for response to anti-programmed cell death-1 (PD-1) drugs in patients with non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Ten patients who had undergone curative lung resection and received the anti-PD-1 drugs for the recurrence were enrolled. The cut-off value for PD-L2 (antibody clone 176611) expression on tumor cells was set at 50%. Tumor response was evaluated according to immune-related response criteria. RESULTS: Seven patients (70.0%) were positive for PD-L2. The response rates were 28.6% (2/7) and 33.3% (1/3) in patients with PD-L2-positive and PD-L2-negative NSCLC, respectively. Disease control was obtained in 2 patients despite the programmed cell death-ligand 1 (PD-L1)-negativity (antibody clone 22C3: 0%, antibody clone SP142: 0%), and these tumors expressed PD-L2 (≥1%). CONCLUSION:PD-L2 expression may be a target of immunotherapy in patients with PD-L1-negative NSCLC. Copyright
Authors: S Miwa; T Nojima; A A Alomesen; H Ikeda; N Yamamoto; H Nishida; K Hayashi; A Takeuchi; K Igarashi; T Higuchi; H Yonezawa; Y Araki; S Morinaga; Y Asano; H Tsuchiya Journal: Clin Transl Oncol Date: 2021-02-26 Impact factor: 3.405
Authors: Silvia Pesce; Marco Greppi; Francesco Grossi; Genny Del Zotto; Lorenzo Moretta; Simona Sivori; Carlo Genova; Emanuela Marcenaro Journal: Front Immunol Date: 2019-06-04 Impact factor: 7.561